Phaseline

Targets › RET

RET (Proto-oncogene tyrosine-protein kinase receptor Ret): drug programs, companies and trials

17 programs from 15 companies in 47 trials: 23 Phase 2, 14 Phase 1, 7 Phase 3, 3 Phase 4; Oncology, Gastroenterology; next expected readout Nov 2026.

Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15). In contrast to most receptor tyrosine kinases, RET requires not only its cognate ligands but also coreceptors, for activation. (UniProt, P07949)

Open in Phaseline: the race on RET, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rigel PharmaceuticalsPralsetinib
Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
RET, CCDC6, KIF5BPhase 4NSCLC (Non-small Cell Lung Cancer)Jul 2027
Chia Tai Tianqing Pharmaceutical GroupAL2846 Capsule
Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET
MET, KIT, FLT4, RETPhase 3Thyroid CancerJan 2027
RocheAlectinib
ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor
ALK, RET, EML4Phase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors …Jan 2027
Eli LillySelpercatinib
Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
RET, KIF5B, CCDC6Phase 3Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Solid Tumor; Medullary Thyroid Cancer …Feb 2027
Eli LillySelpercatinib (LY3527723)
Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
RET, KIF5B, CCDC6Phase 3Medullary Thyroid CancerNov 2027
Shouyao Holdings (Beijing) Co. LTDSY-5007
RET inhibitor
RETPhase 3Non-Small Cell Lung Cancer–
Jiangxi Provincial Cancer HospitalAnlotinib hydrochloride
Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT)
VEGFR, FGFR, RET, KITPhase 2Esophageal Squamous Cell CarcinomaNov 2026
RochePralsetinib
Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
RET, CCDC6, KIF5BPhase 2Non-small Cell Lung Cancer; Advanced Thyroid Cancer Patients Who Received Target Therapy; Lung Cancer Stage IIINov 2026
Beijing Scitech-Mq PharmaceuticalsST-1898
Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI
VEGFR2, MET, AXL, PDGFRA, RETPhase 2Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell CarcinomaDec 2026
Nanfang Hospital, Southern Medical UniversityDonafenib
multi-targeted tyrosine kinase inhibitor
BRAF, FLT3, RETPhase 2Unresectable Hepatocellular CarcinomaDec 2026
Fudan UniversitySitravatinib
Small molecule inhibitor of receptor tyrosine kinases
PDGFRA, KIT, RET, FLT3Phase 2Metastatic Breast CancerJun 2027
Jiangsu Hansoh PharmaceuticalHS-10365
RET inhibitor
RETPhase 2Nonsmall Cell Lung CancerAug 2027
Eye & ENT Hospital of Fudan UniversityAnlotinib Hydrochloride
Multi-target tyrosine kinase inhibitor
VEGFR, FGFR, RET, KITPhase 2Adenoid Cystic CarcinomaJun 2028
Sichuan Kelun-Biotech BiopharmaceuticalKL590586
RET inhibitor
RETPhase 1Advanced Solid TumorDec 2026
Ellipses PharmaEP0031 (Lunbotinib)
RET inhibitor
RETPhase 1NSCLCMar 2027
Taiho PharmaceuticalTAS0953/HM06
RET inhibitor
RETPhase 1RET-altered Non Small Cell Lung CancerMar 2030
Applied Pharmaceutical ScienceAPS03118
RET inhibitor
RETPhase 1RET-altered Solid Tumors–

Conditions

Non-Small Cell Lung Cancer (5) Carcinoma, Non-Small-Cell Lung (2) Haematological Malignancy (2) Non-small Cell Lung Cancer (2) Medullary Thyroid Cancer (2) Differentiated Thyroid Carcinoma (1) Unresectable or Metastatic Melanoma (1) Advanced Renal Cell Carcinoma (1) Solid Tumors (1) ALK Fusion-positive Solid or CNS Tumors (1) Drug Monitoring (1) Advanced Cancer (1)

Modalities

small molecule (14), mixed (2), antibody (1)

Companies

Roche (2) Eli Lilly (2) Beijing Scitech-Mq Pharmaceuticals (1) Ellipses Pharma (1) Fudan University (1) Taiho Pharmaceutical (1) Jiangxi Provincial Cancer Hospital (1) Nanfang Hospital, Southern Medical University (1) Jiangsu Hansoh Pharmaceutical (1) Shouyao Holdings (Beijing) Co. LTD (1) Rigel Pharmaceuticals (1) Eye & ENT Hospital of Fudan University (1) Chia Tai Tianqing Pharmaceutical Group (1) Applied Pharmaceutical Science (1) Sichuan Kelun-Biotech Biopharmaceutical (1)

Related targets

KIT (4) CCDC6 (4) KIF5B (4) MET (2) PDGFRA (2) FLT3 (2) VEGFR (2) FGFR (2) VEGFR2 (1) AXL (1) ALK (1) EML4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.